ZURICH (Reuters) – Novartis has broadened the indications for its Votubia drug, the corporate stated on Tuesday, when the European Union authorised its use to deal with refractory partial-onset seizures in sufferers with tuberous sclerosis complicated.
Votubia is the primary adjunctive remedy authorised within the EU particularly for partial-onset seizures in youngsters and adults with tuberous sclerosis complicated, the Basel-based prescription drugs firm stated in a press release.
The choice marks the third TSC-related indication for Votubia within the EU, the place it’s also permitted to deal with subependymal big cell astrocytoma and renal angiomyolipomas.
Tuberous sclerosis complicated is a uncommon genetic dysfunction affecting as much as a million individuals worldwide. Approximately 85 % of people with TSC are affected by epilepsy, and uncontrolled seizures related to TSC could be debilitating for sufferers.
(Reporting by John Revill)